1. RESEARCH SCOPE
    • STUDY GOALS
    • SCOPE OF THE MARKET STUDY
    • WHO WILL FIND THIS REPORT USEFUL?
    • STUDY AND FORECASTING YEARS
  2. RESEARCH METHODOLOGY
    • SOURCES OF DATA
      • SECONDARY DATA
      • PRIMARY DATA
    • TOP DOWN APPROACH
    • BOTTOM-UP APPROACH
    • DATA TRIANGULATION
  3. EXECUTIVE SUMMARY
    • MARKET SUMMARY
    • KEY FINDINGS
      • NORTH AMERICA IS THE GLOBAL LEADER IN HUMAN MICROBIOME MARKET
      • PROBIOTICS PRODUCT ARE MAJORLY USED
      • USE OF PERSONALIZED MEDICINES IS INCREASING
  1. MARKET DETERMINANTS
    • MARKET DRIVERS
      • RISING PREVALENCE OF PRECISION MEDICINES
      • FOCUS ON EARLY DISEASE DETECTION AND DIAGNOSIS
      • GROWING PREVALENCE OF CHRONIC DISEASES
    • MARKET RESTRAINTS
      • BARRIERS IN EARLY DETECTION AND DIAGNOSIS
      • LACK OF TECHNOLOGICAL EXPERTISE
      • LACK OF SKILLED PROFESSIONALS AND LACK OF PROPER INFRASTRUCTURE IN MICROBIOME STREAM
      • STRINGENT GOVERNMENT REGULATIONS
    • MARKET OPPORTUNITIES
      • INCREASING INVESTMENT IN NOVEL DRUGS
      • GROWING INVESTMENT IN R&D
      • INCREASE IN LIFESTYLE DISEASES ARE EXPECTED TO DRIVE THE DEMAND FOR NEW AND ADVANCED DRUGS
      • RAPIDLY CHANGING LIFESTYLE IN THE EMERGING COUNTRIES
    • MARKET CHALLENGES
      • LACK OF AWARENESS
      • NEW TECHNOLOGY BARRIER TO ENTER INTO THE MARKET
  1. MARKET SEGMENTATION
    • MARKET BY APPLICATIONS 2018-2026
      • DRUGS
      • DIAGNOSTICS
    • MARKET BY PRODUCTS 2018-2026
      • PROBIOTICS
      • FOODS
      • PREBIOTICS
      • MEDICAL FOODS
      • DIAGNOSTIC DEVICE
      • DRUGS
      • OTHER PRODUCTS
    • MARKET BY DISEASES 2018-2026
      • CANCER
      • OBESITY
      • TYPE 2 DIABETES
      • ULCERATIVE COLITIS
      • CROHN’S DISEASE
      • DIFFICLE INFECTION
      • LACTOSE INTOLERANCE
      • DENTAL CARIES
      • RECURRENT BACTERIAL VAGINOSIS AND UTI
      • SKIN DISORDERS
      • HYPEROXALURIA
      • CELIAC DISEASE
      • UREA CYCLE DISORDER
      • PHENYLKETONURIA
      • NON-ALCOHOLIC STEATOHEPATITIS
      • HEPATIC ENCEPHALOPATHY
  1. KEY ANALYTICS
    • PORTER’S 5 FORCES ANALYSIS
      • THREAT OF NEW ENTRANTS
      • THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
      • BARGAINING POWER OF BUYER
      • BARGAINING POWER OF SUPPLIER
      • INTENSITY OF COMPETITIVE RIVALRY
    • ADVANCES IN MICROBIOME RESEARCH
    • AREA OF FOCUS FOR MICROBIOME BASED DRUGS AND DIAGNOSTICS
    • SUPPLY CHAIN ANALYSIS
    • KEY BUYING CRITERIA
    • REGULATORY FRAMEWORK
    • PRODUCT DEVELOPMENT STRATEGIES
    • ESTIMATION ANALYSIS
    • CHALLENGES IN MICROBIOME DRUG DEVELOPMENT
    • PARENT MARKET ANALYSIS
    • PRODUCTS IN PIPELINE
    • INTELLECTUAL PROPERTY, INVESTMENTS AND COLLABORATIONS
      • INTELLECTUAL PROPERTY
      • INVESTMENTS AND COLLABORATIONS
  1. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • THE UNITED STATES
      • CANADA
    • EUROPE
      • THE UNITED KINGDOM
      • FRANCE
      • GERMANY
      • ITALY
      • SPAIN
      • REST OF EUROPE
    • ASIA PACIFIC
      • CHINA
      • INDIA
      • JAPAN
      • SOUTH KOREA
      • AUSTRALIA
      • REST OF APAC
    • REST OF WORLD
      • LATIN AMERICA
      • MIDDLE EAST & AFRICA
  1. COMPANY PROFILES
    • COMPETITIVE LANDSCAPE
      • MARKET SHARE ANALYSIS
    • 4D PHARMA
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
    • AVIDBIOTICS INC.
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
    • ACTOGENIX NV (ACQUIRED BY INTREXON CORPORATION)
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • AVIDBIOTICS CORP.
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • ENTEROME SA
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • METABIOMICS
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC MOVES
    • MICROBIOME THERAPEUTICS
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC MOVES
    • METABOGEN AB
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • MIOMICS
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
    • OSEL INC
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
    • REBIOTIX
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • RITTER PHARMACEUTICALS, INC
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • SECOND GENOME
      • COMPANY OVERVIEW
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • SYMBERIX INC
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
    • SYMBIOTIX BIOTHERAPIES, INC.
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • VEDANTA BIOSCIENCES, INC.(ACQUIRED BY PURETECH HEALTH PLC)
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES

 

TABLE LIST

TABLE 1       GLOBAL HUMAN MICROBIOME MARKET BY GEOGRAPHY 2018-2022 ($ MILLION)

TABLE 2       GLOBAL HUMAN MICROBIOME MARKET BY GEOGRAPHY 2022-2026 ($ MILLION)

TABLE 3       INCIDENCE OF DIABETES IN THE MAJOR COUNTRIES IN 2016(MILLIONS)

TABLE 4       COMPANIES WORKING TOWARDS DEVELOPING NEW DRUGS

TABLE 5       GLOBAL HUMAN MICROBIOME MARKET BY APPLICATIONS 2018-2022 ($ MILLION)

TABLE 6       GLOBAL HUMAN MICROBIOME MARKET BY APPLICATIONS 2022-2026 ($ MILLION)

TABLE 7       GLOBAL HUMAN MICROBIOME MARKET BY PRODUCTS 2018-2022 ($ MILLION)

TABLE 8       GLOBAL HUMAN MICROBIOME MARKET BY PRODUCTS 2022-2026 ($ MILLION)

TABLE 9       GLOBAL HUMAN MICROBIOME MARKET IN PROBIOTICS BY GEOGRAPHY 2018-2022 ($ MILLION)

TABLE 10     GLOBAL HUMAN MICROBIOME MARKET IN PROBIOTICS BY GEOGRAPHY 2022-2026 ($ MILLION)

TABLE 11     GLOBAL HUMAN MICROBIOME MARKET IN FOODS BY GEOGRAPHY 2018-2022 ($ MILLION)

TABLE 12     GLOBAL HUMAN MICROBIOME MARKET IN FOODS BY GEOGRAPHY 2022-2026 ($ MILLION)

TABLE 13     GLOBAL HUMAN MICROBIOME MARKET IN PREBIOTICS BY GEOGRAPHY 2018-2022 ($ MILLION)

TABLE 14     GLOBAL HUMAN MICROBIOME MARKET IN PREBIOTICS BY GEOGRAPHY 2022-2026 ($ MILLION)

TABLE 15     GLOBAL HUMAN MICROBIOME MARKET IN MEDICAL FOODS BY GEOGRAPHY 2018-2022 ($ MILLION)

TABLE 16     GLOBAL HUMAN MICROBIOME MARKET IN MEDICAL FOODS BY GEOGRAPHY 2022-2026 ($ MILLION)

TABLE 17     GLOBAL HUMAN MICROBIOME MARKET IN DIAGNOSTIC DEVICE BY GEOGRAPHY 2018-2022 ($ MILLION)

TABLE 18     GLOBAL HUMAN MICROBIOME MARKET IN DIAGNOSTIC DEVICE BY GEOGRAPHY 2022-2026 ($ MILLION)

TABLE 19     GLOBAL HUMAN MICROBIOME MARKET IN DRUGS BY GEOGRAPHY 2018-2022 ($ MILLION)

TABLE 20     GLOBAL HUMAN MICROBIOME MARKET IN DRUGS BY GEOGRAPHY 2022-2026 ($ MILLION)

TABLE 21     GLOBAL HUMAN MICROBIOME MARKET IN OTHER PRODUCTS BY GEOGRAPHY 2018-2022 ($ MILLION)

TABLE 22     GLOBAL HUMAN MICROBIOME MARKET IN OTHER PRODUCTS BY GEOGRAPHY 2022-2026 ($ MILLION)

TABLE 23     GLOBAL HUMAN MICROBIOME MARKET BY DISEASES 2018-2022 ($ MILLION)

TABLE 24     GLOBAL HUMAN MICROBIOME MARKET BY DISEASES 2022-2026 ($ MILLION)

TABLE 25     MICROBIOTA ASSOCIATED WITH CANCERS

TABLE 26     MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR CANCER

TABLE 27     MICROBIOTA ASSOCIATED WITH OBESITY

TABLE 28     MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR OBESITY

TABLE 29     MICROBIOTA ASSOCIATED WITH TYPE 2 DIABETES

TABLE 30     MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR TYPE 2 DIABETES

TABLE 31     MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR ULCERATIVE COLITIS

TABLE 32     MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR CROHN’S DISEASE

TABLE 33     MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR CLOSTRIDIUM DIFFICLE INFECTION

TABLE 34     MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR CLOSTRIDIUM DIFFICLE INFECTION

TABLE 35     MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR CLOSTRIDIUM DIFFICLE INFECTION

TABLE 36     MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR RECURRENT BACTERIAL VAGINOSIS AND URINARY TRACT INFECTION

TABLE 37     MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR SKIN DISEASES

TABLE 38     MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR SKIN DISEASES

TABLE 39     MICROBIOTA ASSOCIATED WITH CELIAC DISEASE

TABLE 40     MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR CELIAC DISEASE

TABLE 41     MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR UREA CYCLE DISORDER

TABLE 42     MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR NON-ALCOHOLIC STEATOHEPATITIS

TABLE 43     MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR HEPATIC ENCEPHALOPATHY

TABLE 44     FOCUS AREAS FOR MICROBIOME RESEARCH OF SPECIFIC DISEASES

TABLE 45     MICROBIOME DRUG DEVELOPMENT APPROACHES

TABLE 46     INVESTMENTS IN MICROBIOLOGY

TABLE 47     U.S. PATENTS FOR C. DIFFICLE INFECTION

TABLE 48     U.S. PATENTS ON MICROBIOME-BASED DRUGS FOR IRRITABLE BOWEL SYNDROME

TABLE 49     U.S. PATENTS ON MICROBIOME-BASED DRUGS FOR DIABETES AND OBESITY

TABLE 50     U.S. PATENTS ON MICROBIOME-BASED DRUGS FOR CANCER

TABLE 51     U.S. PATENTS ON MICROBIOME-BASED DRUGS FOR UREA CYCLE DISORDERS

TABLE 52     VENTURE CAPITAL INVESTMENTS IN MICROBIOME START-UPS ($ MILLIONS)

TABLE 53     INDUSTRY COLLABORATIONS IN MICROBIOME-BASED COMPANIES ($ MILLIONS)

TABLE 54     GLOBAL HUMAN MICROBIOME MARKET BY GEOGRAPHY 2018-2022 ($ MILLION)

TABLE 55     GLOBAL HUMAN MICROBIOME MARKET BY GEOGRAPHY 2022-2026 ($ MILLION)

TABLE 56     NORTH AMERICA HUMAN MICROBIOME MARKET 2018-2022 ($ MILLION)

TABLE 57     NORTH AMERICA HUMAN MICROBIOME MARKET 2022-2026 ($ MILLION)

TABLE 58     COLLECTIVE PROGRAMS BY CIHR’S ON HUMAN MICROBIOME IN 2017

TABLE 59     EUROPE HUMAN MICROBIOME MARKET 2018-2022 ($ MILLION)

TABLE 60     EUROPE HUMAN MICROBIOME MARKET 2012-2026 ($ MILLION)

TABLE 61     ASIA PACIFIC HUMAN MICROBIOME MARKET 2018-2022 ($ MILLION)

TABLE 62     ASIA PACIFIC HUMAN MICROBIOME MARKET 2022-2026 ($ MILLION)

TABLE 63     REST OF WORLD HUMAN MICROBIOME MARKET 2018-2022 ($ MILLION)

TABLE 64     REST OF WORLD HUMAN MICROBIOME MARKET 2022-2026 ($ MILLION)

 

FIGURE LIST

FIGURE 1     GLOBAL HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 2     ESTIMATED NUMBER OF PEOPLE WITH CHRONIC CONDITIONS IN UNITED STATES

FIGURE 3     GLOBAL HUMAN MICROBIOME MARKET IN DRUGS 2018-2026 ($ MILLION)

FIGURE 4     GLOBAL HUMAN MICROBIOME MARKET IN DRUGS 2018-2026 ($ MILLION)

FIGURE 5     GLOBAL HUMAN MICROBIOME MARKET IN PROBIOTICS 2018-2026 ($ MILLION)

FIGURE 6     GLOBAL HUMAN MICROBIOME MARKET IN FOODS 2018-2026 ($ MILLION)

FIGURE 7     GLOBAL HUMAN MICROBIOME MARKET IN PREBIOTICS 2018-2026 ($ MILLION)

FIGURE 8     GLOBAL HUMAN MICROBIOME MARKET IN MEDICAL FOODS 2018-2026 ($ MILLION)

FIGURE 9     GLOBAL HUMAN MICROBIOME MARKET IN DIAGNOSTIC DEVICE 2018-2026 ($ MILLION)

FIGURE 10   GLOBAL HUMAN MICROBIOME MARKET IN DRUGS 2018-2026 ($ MILLION)

FIGURE 11   GLOBAL HUMAN MICROBIOME MARKET IN OTHER PRODUCTS 2018-2026 ($ MILLION)

FIGURE 12   GLOBAL HUMAN MICROBIOME MARKET IN CANCER 2018-2026 ($ MILLION)

FIGURE 13   GLOBAL HUMAN MICROBIOME MARKET IN OBESITY 2018-2026 ($ MILLION)

FIGURE 14   GLOBAL HUMAN MICROBIOME MARKET IN TYPE 2 DIABETES 2018-2026 ($ MILLION)

FIGURE 15   GLOBAL HUMAN MICROBIOME MARKET IN ULCERATIVE COLITIS 2018-2026 ($ MILLION)

FIGURE 16   GLOBAL HUMAN MICROBIOME MARKET IN CROHN’S DISEASE 2018-2026 ($ MILLION)

FIGURE 17   GLOBAL HUMAN MICROBIOME MARKET IN C. DIFFICLE INFECTION 2018-2026 ($ MILLION)

FIGURE 18   GLOBAL HUMAN MICROBIOME MARKET IN LACTOSE INTOLERANCE 2018-2026 ($ MILLION)

FIGURE 19   GLOBAL HUMAN MICROBIOME MARKET IN DENTAL CARIES 2018-2026 ($ MILLION)

FIGURE 20   GLOBAL HUMAN MICROBIOME MARKET IN RECURRENT BACTERIAL VAGINOSIS AND UTI  2018-2026 ($ MILLION)

FIGURE 21   GLOBAL HUMAN MICROBIOME MARKET IN SKIN DISORDERS 2018-2026 ($ MILLION)

FIGURE 22   MICROBES INVOLVED IN HEALTHY FACIAL SKIN (PERCENT MICROBES)

FIGURE 23   GLOBAL HUMAN MICROBIOME MARKET IN HYPEROXALURIA 2018-2026 ($ MILLION)

FIGURE 24   GLOBAL HUMAN MICROBIOME MARKET IN CELIAC DISEASE 2018-2026 ($ MILLION)

FIGURE 25   GLOBAL HUMAN MICROBIOME MARKET IN UREA CYCLE DISORDER 2018-2026 ($ MILLION)

FIGURE 26   GLOBAL HUMAN MICROBIOME MARKET IN PHENYLKETONURIA 2018-2026 ($ MILLION)

FIGURE 27   GLOBAL HUMAN MICROBIOME MARKET IN NON-ALCOHOLIC STEATOHEPATITIS 2018-2026 ($ MILLION)

FIGURE 28   GLOBAL HUMAN MICROBIOME MARKET IN HEPATIC ENCEPHALOPATHY 2018-2026 ($ MILLION)

FIGURE 29   HEALTHCARE EXPENDITURE IN THE U.S. 2015-2025 (% OF GDP)

FIGURE 30   RESEARCH AND DEVELOPMENT SPENDING IN THE LIFE SCIENCE 2014-2016 ($ BILLION)

FIGURE 31   NUMBER OF PATENTS GRANTED FOR WORLDWIDE MICROBIOME-BASED DRUGS 2010-2017

FIGURE 32   NORTH AMERICA HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 33   THE U.S. HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 34   CANADA HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 35   EUROPE HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 36   THE UNITED KINGDOM HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 37   FRANCE HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 38   GERMANY HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 39   ITALY HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 40   SPAIN HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 41   REST OF EUROPE HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 42   ASIA PACIFIC HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 43   CHINA HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 44   INDIA HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 45   JAPAN HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 46   SOUTH KOREA HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 47   AUSTRALIA HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 48   REST OF APAC HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 49   REST OF WORLD HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 50   LATIN AMERICA HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 51   MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET 2018-2026 ($ MILLION)

FIGURE 52   MARKET SHARE ANALYSIS OF GLOBAL HUMAN MICROBIOME MARKET 2017(%)